

C  
B4  
tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, acute lymphocytic leukemia, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic myelocytic, leukemia, chronic lymphocytic leukemia, polycythemia vera, Hodgkin's disease lymphoma, non-Hodgkin's disease lymphoma, multiple myeloma, Waldenström's macroglobulinemia, and heavy chain disease.

---

**REMARKS**

The Examiner has required an election under 35 U.S.C. § 121 of one of the following inventions:

- |           |   |
|-----------|---|
| Group I   | Claims 1-4, 6-9, and 29, drawn to a polypeptide non-covalently associated with an antigenic molecule.       |
| Group II  | Claim 5, drawn to a fusion protein comprising a alpha 2 macroglobulin peptide and an antigenic molecule.    |
| Group III | Claims 10-11, 13 and 14, drawn to a recombinant cell transformed with alpha 2 macroglobulin.                |
| Group IV  | Claims 12-14, drawn to a recombinant cell transformed with alpha 2 macroglobulin and an antigenic molecule. |
| Group V   | Claims 15-18, drawn to a method of preparing a complex of alpha 2 macroglobulin and antigenic molecules.    |
| Group VI  | Claims 19-28 and 30-34, drawn to a method of treating or preventing infectious diseases.                    |

Group VII      Claims 35-36, drawn to a method of treating autoimmune disorders.

In response to the Restriction Requirement, Applicants elect to pursue the subject matter of the claims of group I, claims 1-4, 6-9, and 29, drawn to a polypeptide non-covalently associated with an antigenic molecule. By the amendment made herein, claims 5, 5, 10-28, and 30-36 have been canceled as drawn to non-elected subject matter, without prejudice to pursue the subject matter of the non-elected claims in other applications. Claims 6 and 29 have also been canceled without prejudice. Claims 1, 3, and 7 have been amended, and new claims 37-43 have been added, to clarify the invention. A marked-up version of the claim amendments, with additions indicated by underlining and deletions indicated by brackets, is provided herewith as Exhibit A. A copy of the claims that will pending upon entry of the amendment made herein is provided herewith as Exhibit B.

The new and amended claims are fully supported in the specification as originally filed. For example, support for the amendments to claims 1 and 7 reciting the term “purified molecular complex” is found at page 8, line 27 through page 9, line 5; page 16, lines 1 and 2; and page 28, lines 4-10. Support for the amendments to claims 1, 3 and 7 reciting the phrase “proliferative cell disorder” is found at page 15, line 3, and page 53, lines 9-12.

Support for new claims 37 and 38 is found at page 8, lines 13-18. Support for claim 39 is found in claim 4 as originally filed. Support for claim 40 is found at page 16, lines 1 and 2. Support for claim 41 is found at page 52, line 6 through page 53, line 7. Support for claim 42 is found at page 53, lines 10-30. No new matter has been added by the amendments to the claims.

---

Applicants respectfully request that the present amendments and remarks be entered and made of record in the instant application. An early allowance of the application is earnestly requested. Please charge the required fee, as estimated on the accompanying amendment fee transmittal sheet, to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date: October 23, 2002

Adriane M. Antler 32,605  
Adriane M. Antler (Reg. No.)

By: Eileen E. Falvey 46,097  
Eileen E. Falvey (Reg. No.)

**PENNIE & EDMONDS** LLP  
1155 Avenue of the Americas  
New York, N.Y. 10036-2711  
(212) 790-9090

Enclosure